VAERS Explorer
Back to explore

Report #2890367

Received Mar 23, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
Recovered
Unknown
Vaccinated
Onset
Days to onset
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
TYPTYPHOID LIVE ORAL TY21A (VIVOTIF)BERNA BIOTECH, LTD.1UnknownPO / MO

Symptoms (1)

Incomplete course of vaccination

Symptom narrative

The patient reports that it has been 1.5 weeks since taking the first dose of Vivotif and no further doses taken; Case reference number US-BN-2024-002457 is a spontaneous case initially received from a consumer via agency (reference number: USBAV24-2323) on 10-Sep-2024 and concerns a male patient of unknown age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, reported as a week and a half ago, the patient took the first dose of Vivotif (batch number: unknown), at an unknown dose, orally, for protection against typhoid fever. As reported, the patient took the first dose of Vivotif, but a road trip came up and since the vaccine needed to be refrigerated, the patient did not bring it on the trip and was wondering if to continue with the remaining doses on alternate days or to do the series over (explicitly coded as 'incomplete course of vaccination'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240910-0a8bbe to US-BAVARIAN NORDIC A/S-US-BN-2024-002457, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A male patient of unknown age took the first dose of Vivotif for protection against typhoid fever, but a road trip came up and since the vaccine needed to be refrigerated, the patient did not bring it on the trip and was wondering if to continue with the remaining doses on alternate days or to do the series over, which is considered as incomplete course of vaccination. It was unknown if the patient experienced any adverse event due to Vivotif. Incomplete course of vaccination is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unknown age took the first dose of Vivotif for protection against typhoid fever, but a road trip came up and since the vaccine needed to be refrigerated, the patient did not bring it on the trip and was wondering if to continue with the remaining doses on alternate days or to do the series over, which is considered as incomplete course of vaccination. It was unknown if the patient experienced any adverse event due to Vivotif. Incomplete course of vaccination is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.

Medical history

Comments: None.